ARCHIVES

FDA Consider Regulation of CME Programs Paid for By Drug Companies; Goal To Limit Promotion

This article is from The Cancer Letter archive.

Vol. 18 No. 01 | January 3, 1992

Download PDF Visit The Full Archive

Related Articles

Klausner To Serve As Advisor On Bioterrorism For NAS.

January 4, 2002

DeVita To continue Discussions On Expanded Chops Despite ACCC Coolness; Would Go To DRCCA Board

March 27, 1981

FDA Approves Tamoxifen For DCIS Folowing Breast Surgery And Radiation.

July 28, 2000

NCI Clinical Trials Working Group is looking for pragmatic solutions to improve cancer clinical trials system, Institute official says.

September 24, 2004

SWOG Opens Phase II Trial Of CuraGen’s HDAC Inhibitor For B-Cell Lymphoma

September 29, 2006

Funding opportunities listed.

January 16, 2004